Multicenter consortium to define the single-cell activity landscape of fibrolamellar carcinoma.

Timeframe: 2022 – 2024 Goal: Advance immunotherapy for FLC, by defining the most promising immunological targets that can be translated into effective cell-based immunotherapies Principal Investigators: Praveen Sethupathy, PhD, Biomedical Sciences, Cornell University; Mark Yarchoan, MD, Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University; Paul G. Thomas, PhD, Immunology, St. Jude Children’s Research Hospital …

Read more

Defining the potential of DNAJB1-PRKACA fusion-specific T cells across human populations

Timeframe: 2022 – 2024 Goal: Advance immunotherapy for FLC, by defining the most promising immunological targets that can be translated into effective cell-based immunotherapies Principal Investigator: Paul G. Thomas, PhD, Immunology, St. Jude Faculty New immunotherapeutic approaches have produced spectacular outcomes for a small subset of tumors, including certain melanomas, lung cancers, and leukemias, but these …

Read more